Summit Therapeutics Inc (NASDAQ:SMMT)’s traded shares stood at 9.12 million during the latest session, with the company’s beta value hitting -1.11. At the last check today, the stock’s price was $27.31, to imply an increase of 20.29% or $4.61 in intraday trading. The SMMT share’s 52-week high remains $24.07, putting it 11.86% up since that peak but still an impressive 94.1% since price per share fell to its 52-week low of $1.61. The company has a valuation of $19.78B, with an average of 9.27 million shares in intraday trading volume over the past 10 days and average of 3.32 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Summit Therapeutics Inc (SMMT), translating to a mean rating of 1.00. Of 1 analyst(s) looking at the stock, 0 analyst(s) give SMMT a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 1 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.07.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Summit Therapeutics Inc (NASDAQ:SMMT) trade information
After registering a 20.29% upside in the latest session, Summit Therapeutics Inc (SMMT) has traded red over the past five days. The 5-day price performance for the stock is 118.44%, and 142.71% over 30 days. With these gigs, the year-to-date price performance is 946.17%. Short interest in Summit Therapeutics Inc (NASDAQ:SMMT) saw shorts transact 17.26 million shares and set a 8.77 days time to cover.
The extremes give us $14 and $14 for target low and target high price respectively. As such, SMMT has been trading 48.74% off suggested target high and 48.74% from its likely low.
Summit Therapeutics Inc (SMMT) estimates and forecasts
Looking at statistics comparing Summit Therapeutics Inc share performance against respective industry, we note that the company has underperformed competitors. Summit Therapeutics Inc (SMMT) shares are 505.43% up over the last 6 months, with its year-to-date growth rate lower than industry average at -107.69% against 20.00%.
SMMT Dividends
Summit Therapeutics Inc has its next earnings report out on 2024-Nov-05. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Summit Therapeutics Inc (NASDAQ:SMMT)’s Major holders
Summit Therapeutics Inc insiders hold 88.14% of total outstanding shares, with institutional holders owning 10.52% of the shares at 88.70% float percentage. In total, 10.52% institutions holds shares in the company, led by BAKER BROS. ADVISORS LP. As of 2024-06-30, the company held over 23.22 million shares (or 3.309% of shares), all amounting to roughly $181.13 million.
The next major institution holding the largest number of shares is VANGUARD GROUP INC with 8.82 million shares, or about 1.2566% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $68.78 million.
